# Beam Therapeutics share price today (Beam Therapeutics Inc., BEAM)

> Beam Therapeutics Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BEAM · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/beam

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $25.87 (+16.5% in a year)
- Revenue (Jun 2026): $490 K
- Profit (Jun 2026), incl. one-off: −$123 M (one-off item, see below)
- Operating margin: −25,827.1% (−24,407.9 points on a year ago)
- ROE: −7%, FY25
- ROIC: −21.2%, against a 15.2% cost of capital: −36.4 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Beam Therapeutics share price today? Beam Therapeutics Inc.'s share price was $25.87 at the close on 5 November 2026. It has been moving sideways for 9 weeks. That is 7.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between $22 and $35, and at that close it sat 32% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 6.7 years the share price moved +25% while the S&P 500 moved +121%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Beam Therapeutics pay? Beam Therapeutics Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Beam Therapeutics on? Beam Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Beam Therapeutics profitable? Beam Therapeutics Inc. posted a net loss of $123 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $80.0 M. That loss is 25,036.3% of the quarter's revenue. The same quarter a year earlier lost $102 M. 10 of the last 12 reported quarters were loss-making. Read this profit with care: at −$123 M it is bigger than the quarter's whole revenue of $490 K. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −25,827.1% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Beam Therapeutics make, and is it growing? Beam Therapeutics Inc. reported $490 K of revenue in the Jun 2026 quarter, −94.2% on the same quarter a year earlier. Over 4 years it has grown 28.1% a year on average. The last full year, FY25, came in at $140 M. The last four reported quarters add to $156 M. FY25 revenue was $140 M, +120.0% on the year before. Recent pace: the last four quarters grew +119.5% on average, against 28.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +158.9%, against −33.5% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Beam Therapeutics keep? Beam Therapeutics Inc.'s operating margin was −25,827.1% in the Jun 2026 quarter, 24,407.9 percentage points lower than the same quarter a year ago. Across 5 years it has been between −654.3% and −46.7%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −24,407.9 percentage points on the year while gross margin changed −18,205.3 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Beam Therapeutics' profit turning into cash? Beam Therapeutics Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $345 M of cash, against −$80.0 M of profit. After $14.9 M of spending on assets, free cash was −$360 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Beam Therapeutics' cash go? Beam Therapeutics Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $57.6 M on assets over the last 3 years. Averaged over those years that is 13.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $57.6 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Beam Therapeutics' P/E ratio, and how does it compare with its own history? Beam Therapeutics Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Beam Therapeutics Inc. at 18.5× its FY25 revenue of $140 M. The P/E comes back here once profit turns positive. ## Is the Beam Therapeutics business getting better or worse? Beam Therapeutics Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Beam Therapeutics earn on its capital? Beam Therapeutics Inc. earned a ROE of −7% in FY25. That is up from a low of −51% in FY24. Its return on capital used (ROIC) is 36.4 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −57.2% net margin and 0.09× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −57.2% net margin × 0.09× asset turnover × 1.20× leverage (assets divided by equity) ≈ −6.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −21.2% − 15.2% = −36.4 percentage points. The 15.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Beam Therapeutics have too much debt? Beam Therapeutics Inc. has total debt of $247 M against shareholder equity of $1.1 B as of Jun 2026, so its debt is 0.23× its equity, which is very little. Year by year, that ratio went from 0.18 in FY21 to 0.12 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Beam Therapeutics shareholding pattern? 29.7% of Beam Therapeutics Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 13.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Beam Therapeutics from balance-sheet trouble? For Beam Therapeutics Inc., the Z-score is 3.06. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.06 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Beam Therapeutics rank in its industry? There is no score against its industry: Beam Therapeutics Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Beam Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Beam Therapeutics in size? Beam Therapeutics is the 65th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Zai Lab, AtaiBeckley Inc. and Vericel Corporation. Just below it: Xencor, Inc., Arcus Biosciences, Inc. and NewAmsterdam Pharma Company N.V. ### Biotechnology companies close in size

1. [Zai Lab Limited](https://www.sectoralpha.in/us/stocks/zlab) $2.8 billion
2. [AtaiBeckley Inc.](https://www.sectoralpha.in/us/stocks/atai) $2.7 billion
3. [Vericel Corporation](https://www.sectoralpha.in/us/stocks/vcel) $2.7 billion
4. Beam Therapeutics Inc. $2.6 billion
5. [Xencor, Inc.](https://www.sectoralpha.in/us/stocks/xncr) $2.6 billion
6. [Arcus Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/rcus) $2.5 billion
7. [NewAmsterdam Pharma Company N.V.](https://www.sectoralpha.in/us/stocks/nams) $2.3 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Danaos Corporation](https://www.sectoralpha.in/us/stocks/dac) $2.8 billion · Marine Shipping
2. [NetScout Systems, Inc.](https://www.sectoralpha.in/us/stocks/ntct) $2.8 billion · Software - Infrastructure
3. Beam Therapeutics Inc. $2.8 billion
4. [Trekor Metals Limited](https://www.sectoralpha.in/us/stocks/tgb) $2.8 billion · Copper
5. [Skyward Specialty Insurance Group, Inc.](https://www.sectoralpha.in/us/stocks/skwd) $2.8 billion · Insurance - Property & Casualty

## What else do people ask about Beam Therapeutics? ### What were Beam Therapeutics's latest quarterly results? Beam Therapeutics Inc. reported revenue of $490 K and a net loss of $123 M for the Jun 2026 quarter. Earnings per share were −$1.18. The operating margin was −25,827.1%, 24,407.9 percentage points lower than a year earlier (as of 5 November 2026). ### What is Beam Therapeutics's market cap? Beam Therapeutics Inc.'s market capitalisation is $2.6 B at a stock price of $25.87. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Beam Therapeutics performing? Beam Therapeutics Inc.'s share price has been moving sideways for 9 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Beam Therapeutics's stock price go up? This page does not forecast Beam Therapeutics Inc.'s stock price. What it shows instead: the stock price is $25.87, and it has been moving sideways for 9 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Beam Therapeutics have too much debt? No, Beam Therapeutics Inc. has little debt: its debt is 0.26× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 5 November 2026). ### Where is Beam Therapeutics in its business cycle? Beam Therapeutics Inc.'s FY25 operating margin was −274.6%, against a 5-year range of −654.3% to −46.7%: the middle of its own range, neither a peak nor a low. The latest quarter was −25,827.1%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Beam Therapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Beam Therapeutics a stock worth studying right now? What the numbers show: Beam Therapeutics Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.